Elecoglipron: A Second Oral GLP-1 Pill in Phase 2

A second oral GLP-1 pill has reported phase 2 results. Elecoglipron produced weight reductions ranging from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo.^[1] The figure worth pairing with that is the completion rate: 93% finished the study, but only 75% finished their assigned treatment.

What was tested

VISTA was a multicenter dose-ranging phase 2 trial in adults with obesity or overweight. Participants had a mean age of 48.4 and a mean body weight of 106.9 kg, with a mean BMI of 38.2. Just under three quarters were women.^[1]

A dose-ranging study reports a range for a reason: the arms are not equivalent, and the top arm is not the drug’s result — it is the best of several candidates for what a phase 3 dose might be. Quoting 10.5% alone describes one arm of six.

The tolerability question

Adverse events were reported by between 84% and 98% of participants across the elecoglipron doses, against 84% on placebo. The most common were nausea, constipation, diarrhea, headache and vomiting — the familiar pattern for this class.^[1]

Ninety-three percent stayed in the study. Seventy-five percent stayed on the drug. The gap between those numbers is the finding.

A quarter of participants coming off their assigned treatment inside 26 weeks is a real signal, and it is the kind of detail that disappears from summaries. It does not mean the drug will fail — dose-ranging studies deliberately include doses that turn out to be too high, and finding the ceiling is part of the point. It does mean the eventual phase 3 dose is likely to sit below the one that produced 10.5%.

Why an oral small molecule matters

Semaglutide and tirzepatide are peptides, which is why they are injected and why the oral version of semaglutide needs an absorption carrier and a strict empty-stomach routine — and why other tablets taken alongside it cut its absorption by a third, as we covered in interactions.

A small molecule avoids all of that. It can be manufactured at scale in a way peptides cannot, which bears directly on the shortages this register has tracked from the commercial end. The first of these to reach approval was orforglipron, covered in our Foundayo article; elecoglipron is a second, from a different company, still two phases behind it.